Real-time Estimate
Cboe BZX
19:09:22 27/06/2024 BST
|
5-day change
|
1st Jan Change
|
41.66
USD
|
+1.15%
|
|
+0.64%
|
-19.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
150,473
|
140,172
|
138,395
|
159,703
|
104,403
|
86,152
|
-
|
-
|
Enterprise Value (EV)
1 |
181,813
|
174,584
|
165,982
|
189,770
|
131,531
|
125,194
|
117,827
|
113,193
|
P/E ratio
|
-
|
-15.5
x
|
20
x
|
24.4
x
|
13.3
x
|
-16.2
x
|
8.04
x
|
7.86
x
|
Yield
|
2.62%
|
2.97%
|
3.22%
|
3.04%
|
4.5%
|
5.66%
|
5.94%
|
6.11%
|
Capitalization / Revenue
|
5.76
x
|
3.3
x
|
2.98
x
|
3.46
x
|
2.32
x
|
1.87
x
|
1.87
x
|
1.96
x
|
EV / Revenue
|
6.95
x
|
4.11
x
|
3.58
x
|
4.11
x
|
2.92
x
|
2.72
x
|
2.56
x
|
2.58
x
|
EV / EBITDA
|
18.3
x
|
9.64
x
|
8.1
x
|
9.43
x
|
7.52
x
|
24.3
x
|
6.57
x
|
6.99
x
|
EV / FCF
|
25.1
x
|
13.1
x
|
10.9
x
|
15.9
x
|
10.4
x
|
8.84
x
|
8.62
x
|
8.98
x
|
FCF Yield
|
3.98%
|
7.62%
|
9.18%
|
6.3%
|
9.62%
|
11.3%
|
11.6%
|
11.1%
|
Price to Book
|
2.12
x
|
3.7
x
|
3.73
x
|
5.02
x
|
3.48
x
|
3.97
x
|
3.51
x
|
3.4
x
|
Nbr of stocks (in thousands)
|
2,344,185
|
2,259,752
|
2,219,645
|
2,219,645
|
2,034,758
|
2,027,100
|
-
|
-
|
Reference price
2 |
64.19
|
62.03
|
62.35
|
71.95
|
51.31
|
42.50
|
42.50
|
42.50
|
Announcement Date
|
06/02/20
|
04/02/21
|
04/02/22
|
02/02/23
|
02/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
26,145
|
42,518
|
46,385
|
46,159
|
45,006
|
46,075
|
46,058
|
43,877
|
EBITDA
1 |
9,945
|
18,118
|
20,493
|
20,123
|
17,498
|
5,150
|
17,922
|
16,200
|
EBIT
1 |
8,199
|
17,426
|
19,830
|
19,442
|
16,785
|
4,007
|
16,761
|
15,529
|
Operating Margin
|
31.36%
|
40.98%
|
42.75%
|
42.12%
|
37.3%
|
8.7%
|
36.39%
|
35.39%
|
Earnings before Tax (EBT)
1 |
4,975
|
-6,871
|
8,098
|
7,713
|
8,440
|
-5,696
|
10,302
|
10,307
|
Net income
1 |
3,439
|
-9,015
|
6,994
|
6,327
|
8,025
|
-5,414
|
10,220
|
10,153
|
Net margin
|
13.15%
|
-21.2%
|
15.08%
|
13.71%
|
17.83%
|
-11.75%
|
22.19%
|
23.14%
|
EPS
2 |
-
|
-3.990
|
3.120
|
2.950
|
3.860
|
-2.627
|
5.286
|
5.408
|
Free Cash Flow
1 |
7,231
|
13,299
|
15,234
|
11,948
|
12,651
|
14,162
|
13,676
|
12,606
|
FCF margin
|
27.66%
|
31.28%
|
32.84%
|
25.88%
|
28.11%
|
30.74%
|
29.69%
|
28.73%
|
FCF Conversion (EBITDA)
|
72.71%
|
73.4%
|
74.34%
|
59.37%
|
72.3%
|
274.97%
|
76.31%
|
77.81%
|
FCF Conversion (Net income)
|
210.26%
|
-
|
217.82%
|
188.84%
|
157.64%
|
-
|
133.82%
|
124.16%
|
Dividend per Share
2 |
1.680
|
1.840
|
2.010
|
2.190
|
2.310
|
2.406
|
2.526
|
2.598
|
Announcement Date
|
06/02/20
|
04/02/21
|
04/02/22
|
02/02/23
|
02/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
11,985
|
11,648
|
11,887
|
11,218
|
11,406
|
11,337
|
11,226
|
10,966
|
11,477
|
11,865
|
11,503
|
11,163
|
11,614
|
11,763
|
11,630
|
EBITDA
1 |
4,832
|
5,305
|
7,812
|
7,424
|
4,288
|
5,030
|
4,268
|
4,539
|
3,816
|
-8,984
|
4,153
|
4,234
|
4,544
|
-
|
-
|
EBIT
1 |
4,670
|
5,267
|
5,229
|
4,836
|
4,110
|
4,857
|
4,251
|
4,360
|
3,630
|
-8,329
|
4,168
|
4,031
|
4,171
|
4,906
|
4,630
|
Operating Margin
|
38.97%
|
45.22%
|
43.99%
|
43.11%
|
36.03%
|
42.84%
|
37.87%
|
39.76%
|
31.63%
|
-70.2%
|
36.23%
|
36.11%
|
35.91%
|
41.71%
|
39.81%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
1,958
|
2,209
|
1,859
|
2,770
|
1,859
|
2,137
|
1,674
|
-11,516
|
1,909
|
1,557
|
1,881
|
-
|
-
|
Net income
1 |
2,372
|
1,278
|
1,421
|
1,606
|
2,022
|
2,262
|
2,073
|
1,928
|
1,762
|
-11,911
|
1,390
|
1,336
|
2,563
|
-
|
-
|
Net margin
|
19.79%
|
10.97%
|
11.95%
|
14.32%
|
17.73%
|
19.95%
|
18.47%
|
17.58%
|
15.35%
|
-100.39%
|
12.09%
|
11.97%
|
22.07%
|
-
|
-
|
EPS
2 |
1.070
|
0.5900
|
0.6600
|
0.7500
|
0.9500
|
1.070
|
0.9900
|
0.9300
|
0.8700
|
-5.890
|
0.8130
|
0.7813
|
1.246
|
1.820
|
1.700
|
Dividend per Share
2 |
0.5400
|
0.5400
|
0.5400
|
0.5400
|
0.5700
|
0.5700
|
0.5700
|
0.5700
|
0.6000
|
0.6000
|
0.6048
|
0.6081
|
0.6148
|
0.6744
|
0.6744
|
Announcement Date
|
04/02/22
|
29/04/22
|
27/07/22
|
25/10/22
|
02/02/23
|
27/04/23
|
27/07/23
|
26/10/23
|
02/02/24
|
25/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
31,340
|
34,412
|
27,587
|
30,067
|
27,128
|
39,043
|
31,676
|
27,041
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.151
x
|
1.899
x
|
1.346
x
|
1.494
x
|
1.55
x
|
7.58
x
|
1.767
x
|
1.669
x
|
Free Cash Flow
1 |
7,231
|
13,299
|
15,234
|
11,948
|
12,651
|
14,162
|
13,676
|
12,606
|
ROE (net income / shareholders' equity)
|
24.5%
|
33%
|
45.7%
|
49.4%
|
51.6%
|
4.17%
|
77.3%
|
66.3%
|
ROA (Net income/ Total Assets)
|
-
|
11.9%
|
14.8%
|
16%
|
8.36%
|
-4.45%
|
11.1%
|
10.6%
|
Assets
1 |
-
|
-75,809
|
47,265
|
39,445
|
95,989
|
121,807
|
92,264
|
95,904
|
Book Value Per Share
2 |
30.30
|
16.80
|
16.70
|
14.30
|
14.70
|
10.70
|
12.10
|
12.50
|
Cash Flow per Share
2 |
4.710
|
6.220
|
7.300
|
6.090
|
6.670
|
8.990
|
8.200
|
7.570
|
Capex
1 |
836
|
753
|
973
|
1,118
|
1,209
|
1,153
|
1,134
|
1,084
|
Capex / Sales
|
3.2%
|
1.77%
|
2.1%
|
2.42%
|
2.69%
|
2.5%
|
2.46%
|
2.47%
|
Announcement Date
|
06/02/20
|
04/02/21
|
04/02/22
|
02/02/23
|
02/02/24
|
-
|
-
|
-
|
Last Close Price
42.5
USD Average target price
53.19
USD Spread / Average Target +25.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +55.05% | 811B | | +43.62% | 640B | | -7.14% | 353B | | +17.85% | 333B | | +8.92% | 302B | | +16.30% | 246B | | +2.41% | 225B | | +12.47% | 218B | | +8.57% | 168B |
Other Pharmaceuticals
|